Capricor Therapeutics, Inc. — Cyborg Score 7/10

Strong
Biotechnology - Regenerative Medicine & Cell Therapy

Strategic Profile

Deramiocel has demonstrated potent immunomodulatory and anti-fibrotic effects in helping preserve cardiac and skeletal muscle function in DMD. Capricor is leveraging its proprietary StealthX™ platform in preclinical development focused on vaccinology and targeted delivery of oligonucleotides, proteins, and small-molecule therapeutics, positioning the company as a multi-pipeline platform player in regenerative medicine.

Cyborg Score Rationale

Capricor announced positive topline results from Phase 3 HOPE-3 trial showing statistically significant improvements in both skeletal and cardiac function. The company has strong regulatory designations and is progressing through FDA review with potential for accelerated approval pathways.

Top Insights

  • Phase 3 HOPE-3 results selected for late-breaking presentation at 2026 MDA Clinical and Scientific Conference (March 8-11, 2026)
  • Deramiocel holds Orphan Drug, RMAT, ATMP, and Rare Pediatric Disease designations, potentially qualifying for Priority Review Voucher upon approval
  • Company submitted HOPE-3 clinical study report to FDA to address Complete Response Letter items and support ongoing BLA review with possible new PDUFA target date assignment
  • HOPE-3 randomized 106 subjects across ambulatory and non-ambulatory DMD cohorts in rigorous double-blind, placebo-controlled trial

Named Competitors

  • Gene therapies and small molecule therapeutics — Alternative modalities for DMD treatment

Recent Developments

  • (February 2026) Phase 3 HOPE-3 clinical study report submitted to FDA supporting BLA review
  • (December 2025) Announced positive topline Phase 3 HOPE-3 results demonstrating statistically significant improvements in skeletal and cardiac function
  • (March 2026) Late-breaking HOPE-3 presentation scheduled for MDA Clinical and Scientific Conference

Open the full interactive Capricor Therapeutics, Inc. report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.

Open report →